Statistics on Biotechnology Use  
Results by fields of operation
Business Sector Biotechnology indicators by branch of activity. 
Unidades: specified in variables

;Total Companies;Services;Industry and Construction;Agriculture;
No. of companies carrying out R&D in Biotechnology;1.348;818;427;103;
%Companies according to biotechnology used: Genetic code;31;39,9;15,9;22,9;
%Companies according to biotechnology used: Functional units;38,4;42,8;33,9;22,2;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;21,7;26,3;13,5;19,1;
%Companies according to biotechnology used: Bioprocesses;50,3;40;74,4;33;
%Companies according to biotechnology used: Sub-cellular organisms;8,2;11,1;4,3;2;
%Companies according to biotechnology used: Bio-computing;24,1;34,1;9,2;6,9;
%Companies according to biotechnology used: Nanobiotechnology;11,8;16,2;5,8;1;
%Companies according to biotechnology used: Other;16,4;18,3;7,8;36,9;
Companies in which biotechnology activities are: Main and/or exclusive;661;529;109;23;
Companies in which biotechnology activities are: A secondary line of business;188;105;69;14;
Companies in which biotechnology activities are: A tool necessary for production;500;184;250;66;
%Company by field(s) of ultimate application of biotechnology use: Human Health;45,8;61,6;25,5;5;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;15,3;16,4;10,9;24,2;
%Company by field(s) of ultimate application of biotechnology use: Food products;31,5;21;51,7;32,1;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;23,7;20,2;21,3;60,7;
%Company by field(s) of ultimate application of biotechnology use: Environment;15,5;16,1;15,1;13,1;
%Company by field(s) of ultimate application of biotechnology use: Industry;13,4;14,2;14,2;4;
Personnel in R&D in biotechnology (no. of persons);15.744;9.783;4.929;1.032;
Personnel in R&D in biotechnology (no. of persons): Research personnel;8.380;6.054;2.067;259;
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;7.364;3.729;2.862;773;
Personnel in R&D in biotechnology (no. of persons). Women;8.725;5.567;2.720;438;
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;4.521;3.331;1.085;104;
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;4.204;2.236;1.635;334;
Personnel in R&D in biotechnology (FTE);11.523,2;7.360,5;3.555,3;607,5;
Personnel in R&D in biotechnology (FTE): Research personnel;6.341,6;4.606,5;1.557,7;177,3;
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;5.181,6;2.753,9;1.997,6;430,2;
Personnel in R&D in biotechnology (FTE). Women;6.552,7;4.194,8;2.088,7;269,2;
Personnel in R&D in biotechnology (FTE). Women: Research personnel;3.464,4;2.518,3;872,8;73,3;
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;3.088,3;1.676,5;1.215,9;195,9;
Internal expenditure on R&D (thousands of euros);1.037.887;632.044;365.151;40.692;
1) By nature of the expense: Current expenses;939.471;572.886;329.570;37.015;
1.1) Remuneration to research personnel;321.525;220.159;91.852;9.514;
1.2) Remuneration to technical and auxiliary personnel;194.656;95.001;86.840;12.816;
1.3) Other current expenses;423.290;257.726;150.878;14.686;
2) By nature of the expense: Capital expenses;98.416;59.158;35.581;3.677;
2.1) Land and buildings;10.150;6.669;2.905;577;
2.2) Equipment and instruments;72.538;40.536;30.157;1.845;
2.3) Acquisition of specific R&D software;5.713;3.849;1.726;138;
2.4) Otros productos de propiedad intelectual específicos para I+D;10.015;8.104;794;1.117;
1.1) By origin of the funds: Own funds;711.037;360.440;315.867;34.730;
1.2) By origin of the funds: From companies;121.595;109.172;7.824;4.600;
1.3) By origin of the funds: Public Administration funds;107.422;91.468;14.662;1.292;
1.4) By origin of the funds: From Universities;192;182;11;0;
1.5) By origin of the funds: From non profit private institutions;10.756;10.585;171;0;
1.6) By origin of the funds: Foreign funds;86.884;60.196;26.617;70;
Purchase of R&D services in biotechnology (thousands of euros);145.440;75.379;68.977;1.085;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;95.870;52.783;42.361;726;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;49.570;22.595;26.616;359;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;39,8;48,3;26,8;25;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;12,5;12,2;13,6;10;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;18,5;19,9;16,4;16;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;11,2;11,4;10,8;11,9;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;15,6;18;11,7;12;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;16,5;19,9;10,7;13,9;
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;16,1;16,3;15,7;15,8;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;40;43,1;34,9;37;
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;53,9;57,8;46,9;51,9;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;21,5;22,1;19;26,8;
% Companies with income of an international origin related to biotechnological activities;22,2;24,1;22,3;7;
% Turnover representing income of an international origin related to biotechnological activities;1,9;5,8;1,5;2,4;
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;65,5;60,2;67,5;68,3;
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;34,5;39,8;32,5;31,7;
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;86,3;84;87,3;85;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;12,2;11,9;12,6;0;
% Income of an international origin related with activities according to the classification: Operating source abroad;1,1;3,8;0,1;0;
% Income of an international origin related with activities according to the classification: Other;0,4;0,3;0;15;
Notas:
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute